Correction of Th1-dominant Cytokine Profiles by High-dose Dexamethasone in Patients with Chronic Idiopathic Thrombocytopenic Purpura

[1]  F. Mandelli,et al.  Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. , 2007, Blood.

[2]  I. Bruce,et al.  Activation of transforming growth factor-β1 and early atherosclerosis in systemic lupus erythematosus , 2006, Arthritis research & therapy.

[3]  M. Varma,et al.  Management of adult idiopathic thrombocytopenic purpura. , 2006, Clinical advances in hematology & oncology : H&O.

[4]  R. Ware,et al.  Elevated numbers of gamma-delta (γδ+) T lymphocytes in children with immune thrombocytopenic purpura , 1994, Journal of Clinical Immunology.

[5]  Z. Han,et al.  Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. , 2005, Haematologica.

[6]  F. Borst,et al.  High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults , 2004, Annals of Hematology.

[7]  M. Theodoropoulou,et al.  Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. , 2004, Blood.

[8]  H. Amagai,et al.  High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura , 2003, European journal of haematology.

[9]  R. Wong,et al.  Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. , 2003, New England Journal of Medicine.

[10]  N. Xing,et al.  Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. , 2003, Blood.

[11]  W. Ouwehand,et al.  Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy , 2003, British journal of haematology.

[12]  G. Gutiérrez-Espíndola,et al.  High doses of dexamethasone in adult patients with idiopathic thrombocytopenic purpura. , 2003, Archives of medical research.

[13]  H. Wadenvik,et al.  Reduced transforming growth factor‐β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura , 2002, British journal of haematology.

[14]  G. Marshall,et al.  Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[15]  H. Wadenvik,et al.  A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura , 2000, Annals of Hematology.

[16]  S. Nomura,et al.  Plasma‐soluble Fas (APO‐1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura , 2000, European journal of haematology.

[17]  H. Wadenvik,et al.  A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. , 2000, Annals of hematology.

[18]  J. Wahlström,et al.  Role of the T cell receptor in idiopathic thrombocytopenic purpura (ITP) , 1998, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[19]  J. Andersson.  Cytokines in idiopathic thrombocytopenic purpura (ITP) , 1998, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[20]  Y. Ikeda,et al.  Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. , 1998, The Journal of clinical investigation.

[21]  A. Lazarus,et al.  The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. , 1998, Transfusion science.

[22]  D. Umetsu,et al.  Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. , 1998, Journal of immunology.

[23]  J. George,et al.  Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults , 1998 .

[24]  Y. Aslan,et al.  Plasma soluble interleukin‐2 receptor levels in patients with idiopathic thrombocytopenic purpura , 1998, American journal of hematology.

[25]  J. George,et al.  Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. , 1998, Annals of medicine.

[26]  J. S. Chen,et al.  Pulsed High‐Dose Dexamethasone Therapy in Children with Chronic Idiopathic Thrombocytopenic Purpura , 1997, Journal of pediatric hematology/oncology.

[27]  A. Dickinson,et al.  Effects of interferon-α therapy on immune parameters in immune thrombocytopenic purpura , 1996 .

[28]  I. Adcock,et al.  Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. , 1995, The American journal of physiology.

[29]  M. Álvarez-Mon,et al.  The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency , 1993, British journal of haematology.

[30]  J. Semple,et al.  Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. , 1991, Blood.